MX2014006947A - Composiciones antimicrobianas que comprenden dgla, 15-ohepa y/o 15-hetre y metodos de uso de las mismas. - Google Patents
Composiciones antimicrobianas que comprenden dgla, 15-ohepa y/o 15-hetre y metodos de uso de las mismas.Info
- Publication number
- MX2014006947A MX2014006947A MX2014006947A MX2014006947A MX2014006947A MX 2014006947 A MX2014006947 A MX 2014006947A MX 2014006947 A MX2014006947 A MX 2014006947A MX 2014006947 A MX2014006947 A MX 2014006947A MX 2014006947 A MX2014006947 A MX 2014006947A
- Authority
- MX
- Mexico
- Prior art keywords
- ohepa
- hetre
- dgla
- methods
- antimicrobial compositions
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- IUKXMNDGTWTNTP-RHDCIPCHSA-N 15-HETrE Chemical compound CCCCCC(O)\C=C\C=C/C\C=C/CCCCCCC(O)=O IUKXMNDGTWTNTP-RHDCIPCHSA-N 0.000 title 1
- 230000000845 anti-microbial effect Effects 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- HOBAELRKJCKHQD-UHFFFAOYSA-N (8Z,11Z,14Z)-8,11,14-eicosatrienoic acid Natural products CCCCCC=CCC=CCC=CCCCCCCC(O)=O HOBAELRKJCKHQD-UHFFFAOYSA-N 0.000 abstract 1
- IUKXMNDGTWTNTP-OAHXIXLCSA-N 15(S)-HETrE Chemical compound CCCCC[C@H](O)\C=C\C=C/C\C=C/CCCCCCC(O)=O IUKXMNDGTWTNTP-OAHXIXLCSA-N 0.000 abstract 1
- 230000003115 biocidal effect Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 235000014113 dietary fatty acids Nutrition 0.000 abstract 1
- HOBAELRKJCKHQD-QNEBEIHSSA-N dihomo-γ-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCCCC(O)=O HOBAELRKJCKHQD-QNEBEIHSSA-N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 229930195729 fatty acid Natural products 0.000 abstract 1
- 239000000194 fatty acid Substances 0.000 abstract 1
- 150000004665 fatty acids Chemical class 0.000 abstract 1
- 206010040872 skin infection Diseases 0.000 abstract 1
- 230000029663 wound healing Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261591036P | 2012-01-26 | 2012-01-26 | |
| US13/478,990 US20120264705A1 (en) | 2012-01-26 | 2012-05-23 | Antimicrobial compositions comprising 15-hetre and methods of use thereof |
| PCT/US2013/023201 WO2013112876A1 (en) | 2012-01-26 | 2013-01-25 | Antimicrobial compositions comprising dgla, 15-ohepa and/or 15-hetre and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2014006947A true MX2014006947A (es) | 2015-03-05 |
Family
ID=47006834
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014006947A MX2014006947A (es) | 2012-01-26 | 2013-01-25 | Composiciones antimicrobianas que comprenden dgla, 15-ohepa y/o 15-hetre y metodos de uso de las mismas. |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20120264705A1 (https=) |
| EP (1) | EP2806868A4 (https=) |
| JP (3) | JP6557009B2 (https=) |
| KR (1) | KR20140117379A (https=) |
| CN (1) | CN104114166A (https=) |
| AU (1) | AU2013211982A1 (https=) |
| BR (1) | BR112014018421A8 (https=) |
| CA (1) | CA2857046A1 (https=) |
| HK (1) | HK1198921A1 (https=) |
| IL (1) | IL232777A0 (https=) |
| MX (1) | MX2014006947A (https=) |
| PH (1) | PH12014501693A1 (https=) |
| RU (1) | RU2014134720A (https=) |
| SG (1) | SG11201404088TA (https=) |
| WO (1) | WO2013112876A1 (https=) |
| ZA (1) | ZA201403948B (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0907413D0 (en) | 2009-04-29 | 2009-06-10 | Equateq Ltd | Novel methods |
| RU2014119948A (ru) * | 2011-10-19 | 2015-11-27 | Дигнити Сайенсиз Лимитед | ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ DGLA И/ИЛИ 15-HETrE, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |
| US8293790B2 (en) * | 2011-10-19 | 2012-10-23 | Dignity Sciences Limited | Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof |
| US9855236B2 (en) | 2011-10-19 | 2018-01-02 | Ds Biopharma Limited | Pharmaceutical compositions comprising DGLA and/or 15-HETrE and methods of use thereof |
| GB201301626D0 (en) * | 2013-01-30 | 2013-03-13 | Dignity Sciences Ltd | Composition comprising 15-OHEPA and methods of using the same |
| GB201307082D0 (en) * | 2013-04-19 | 2013-05-29 | Dignity Sciences Ltd | Pharmaceutical composition comprising 15-HETrE and methods of using the same |
| WO2015042442A1 (en) * | 2013-09-19 | 2015-03-26 | Dignity Sciences Limited | Pharmaceutical compositions comprising dha, epa, and/or gla and an antibiotic agent and methods of use thereof |
| JP2016538288A (ja) | 2013-11-15 | 2016-12-08 | ディグニティ サイエンシス リミテッド | 多価不飽和ヒドロキシ脂肪酸の薬学的に許容される塩 |
| EP3091959A4 (en) * | 2014-01-10 | 2017-09-20 | Dignity Sciences Limited | Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same |
| US9682055B2 (en) | 2014-06-04 | 2017-06-20 | Dignity Sciences Limted | Pharmaceutical compositions comprising DGLA and use of same |
| LT6177B (lt) | 2014-10-10 | 2015-07-27 | Uab "Biocentras" | Fermentų kompleksų išskyrimas iš steptomyces gougerotii 101, daugiafermentinių biopreparatų ruošimas bei taikymas |
| MA41120A (fr) | 2014-12-02 | 2017-10-10 | Afimmune Ltd | Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci |
| US20180008567A1 (en) * | 2015-01-16 | 2018-01-11 | Afimmune Limited | Compositions comprising 15-hepe and methods of using the same |
| ES2851525T3 (es) | 2015-07-21 | 2021-09-07 | Afimmune Ltd | Composiciones que comprenden 15(S)-HEPE para su uso en la sensibilización de las células cancerosas a la radioterapia |
| CA3129008A1 (en) | 2015-12-18 | 2017-06-22 | Afimmune Limited | Compositions comprising 15-hepe and methods of using the same |
| US20200206173A1 (en) | 2017-08-30 | 2020-07-02 | Conopco, Inc., D/B/A Unilever | A personal care composition |
| US20210315851A1 (en) | 2020-04-03 | 2021-10-14 | Afimmune Limited | Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4344930A (en) * | 1975-10-30 | 1982-08-17 | Colgate-Palmolive Company | Skin care sponge |
| JP4926310B2 (ja) * | 1996-02-15 | 2012-05-09 | エルテーベー４・スウェーデン・アクチェボラーグ | 抗ウイルス薬および抗腫瘍薬としてのロイコトリエンｂ４またはその類似体の使用 |
| US5789441A (en) * | 1996-02-15 | 1998-08-04 | Virocell Inc. | Leukotriene B4 as an antiviral and anti-neoplastic agent |
| US6190645B1 (en) * | 1999-07-15 | 2001-02-20 | Playtex Products, Inc. | Sunscreen for the scalp hair and hair |
| US20030073930A1 (en) * | 2001-10-17 | 2003-04-17 | Morrissey Gerald R. | Methods and device for preventing or healing injured nipples or areolas in mammalian females or for obtaining samples from nipples in mammalian females |
| US20030105445A1 (en) * | 2001-11-30 | 2003-06-05 | Kimberly-Clark Worldwide, Inc. | Breast pad assembly containing a skin benefit ingredient |
| WO2005102309A2 (en) * | 2004-04-26 | 2005-11-03 | Ltb4 Sweden Ab | In vivo release of endogenous anti-microbial mediators by leukotriene b4 (ltb4) administration |
| CA2674210A1 (en) * | 2005-12-30 | 2007-07-12 | Intradigm Corporation | Sirna compositions promoting scar-free wound healing of skin and methods for wound treatment |
| CA2670158A1 (en) * | 2006-11-23 | 2008-05-29 | Cargill, Incorporated | Natural equivalent of chemically modified starch |
| CN101715349B (zh) * | 2007-05-08 | 2012-07-18 | 美国Rq生物科技有限公司 | 治疗革兰氏阴性细菌感染的治疗组合物及方法 |
| EP2159732A1 (en) * | 2008-08-21 | 2010-03-03 | Thomson Licensing | Method and device for code obfuscation |
| GB0907413D0 (en) * | 2009-04-29 | 2009-06-10 | Equateq Ltd | Novel methods |
| US8637298B2 (en) * | 2009-06-16 | 2014-01-28 | E I Du Pont De Nemours And Company | Optimized strains of yarrowia lipolytica for high eicosapentaenoic acid production |
| US8293790B2 (en) * | 2011-10-19 | 2012-10-23 | Dignity Sciences Limited | Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof |
-
2012
- 2012-05-23 US US13/478,990 patent/US20120264705A1/en not_active Abandoned
-
2013
- 2013-01-25 SG SG11201404088TA patent/SG11201404088TA/en unknown
- 2013-01-25 CA CA2857046A patent/CA2857046A1/en not_active Abandoned
- 2013-01-25 EP EP13741302.7A patent/EP2806868A4/en not_active Withdrawn
- 2013-01-25 KR KR1020147018192A patent/KR20140117379A/ko not_active Abandoned
- 2013-01-25 JP JP2014554868A patent/JP6557009B2/ja not_active Expired - Fee Related
- 2013-01-25 MX MX2014006947A patent/MX2014006947A/es unknown
- 2013-01-25 WO PCT/US2013/023201 patent/WO2013112876A1/en not_active Ceased
- 2013-01-25 RU RU2014134720A patent/RU2014134720A/ru not_active Application Discontinuation
- 2013-01-25 HK HK14112445.0A patent/HK1198921A1/xx unknown
- 2013-01-25 BR BR112014018421A patent/BR112014018421A8/pt not_active Application Discontinuation
- 2013-01-25 CN CN201380006224.7A patent/CN104114166A/zh active Pending
- 2013-01-25 AU AU2013211982A patent/AU2013211982A1/en not_active Abandoned
-
2014
- 2014-02-21 US US14/186,200 patent/US20140171358A1/en not_active Abandoned
- 2014-05-25 IL IL232777A patent/IL232777A0/en unknown
- 2014-05-29 ZA ZA2014/03948A patent/ZA201403948B/en unknown
- 2014-07-25 PH PH12014501693A patent/PH12014501693A1/en unknown
-
2017
- 2017-11-10 JP JP2017217054A patent/JP2018065818A/ja active Pending
-
2019
- 2019-09-27 JP JP2019176350A patent/JP2020023513A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| HK1198921A1 (en) | 2015-06-19 |
| US20140171358A1 (en) | 2014-06-19 |
| JP2015504921A (ja) | 2015-02-16 |
| JP2018065818A (ja) | 2018-04-26 |
| JP2020023513A (ja) | 2020-02-13 |
| JP6557009B2 (ja) | 2019-08-07 |
| CN104114166A (zh) | 2014-10-22 |
| EP2806868A1 (en) | 2014-12-03 |
| BR112014018421A2 (https=) | 2017-06-20 |
| KR20140117379A (ko) | 2014-10-07 |
| RU2014134720A (ru) | 2016-03-20 |
| CA2857046A1 (en) | 2013-08-01 |
| BR112014018421A8 (pt) | 2017-07-11 |
| EP2806868A4 (en) | 2015-08-26 |
| PH12014501693A1 (en) | 2014-10-20 |
| SG11201404088TA (en) | 2014-10-30 |
| AU2013211982A1 (en) | 2014-06-19 |
| US20120264705A1 (en) | 2012-10-18 |
| IL232777A0 (en) | 2014-07-31 |
| WO2013112876A1 (en) | 2013-08-01 |
| ZA201403948B (en) | 2015-12-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12014501693A1 (en) | Antimicrobial compositions comprising dgla, 15-ohepa and/or 15-hetre and methods of use thereof | |
| ZA202004764B (en) | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof | |
| WO2017163132A3 (en) | Use of umbilical cord blood derived exosomes for tissue repair | |
| NZ727304A (en) | Compositions and methods of use of phorbol esters for the treatment of stroke | |
| WO2015077503A8 (en) | Autotaxin inhibitor compounds | |
| HK1203356A1 (en) | Pharmaceutical combinations comprising a thionucleotide analog | |
| HK1202415A1 (en) | Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15-hetre and methods of use thereof | |
| PH12019501469A1 (en) | Compositions and methods for treating biofilms | |
| PH12016500024A1 (en) | Bromodomain inhibitor | |
| PH12013501892A1 (en) | Nutritional compositions including branched chain fatty acids for wound healing | |
| IN2014DN07483A (https=) | ||
| MX374477B (es) | Composicion y productos que comprenden celulas senescentes para su uso en la regeneracion de tejidos | |
| WO2015066302A3 (en) | Compositions, methods of use, and methods of treatment | |
| PH12014500859A1 (en) | Pharmaceutical compositions comprising dgla and/or 15-hetre and methods of use thereof | |
| MX353580B (es) | Acido graso monoinsaturado para prevenir y/o tratar las imperfecciones del color de la piel. | |
| WO2015054374A3 (en) | Perforin-2 activators and inhibitors as drug targets for infectious disease and gut inflammation | |
| SG11201909144VA (en) | Bacterial secretome for use in the treatment of skin lesions | |
| WO2014031982A3 (en) | Methods and compositions for treating pain | |
| EP3297435A4 (en) | METHODS FOR PREVENTING COLONIZATION OF TISSUES BY PATHOGENIC AGENTS AND TREATING BIOFILMS ON ANIMAL TISSUES | |
| MX2012007158A (es) | Derivados de peroxidos de dibenzoilo, metodo de preparacion de los mismos, composiciones cosmeticas o dermatologicas que los contienen. | |
| BR112016029761A8 (pt) | composições compreendendo um derivado de ácido quinolona carboxílico e agentes efervescentes, uso das mesmas e forma cristalina do referido derivado | |
| TN2014000484A1 (en) | Dronedarone for use in leishmaniasis, formulations and associations for use in leishmaniasis. | |
| PH12020500472A1 (en) | Autotaxin inhibitor compounds | |
| HK1197736A (en) | Pharmaceutical compositions comprising dgla and/or 15-hetre and methods of use thereof | |
| HK1229697A1 (en) | Synergistic bacterial compositions and methods of production and use thereof |